Insights
Insights From Our Experts
Articles
Is Your Digital Communication Strategy Up to Par?
In today’s competitive global market, pharmaceutical companies cannot afford to waste time or resources on strategies that do not fit patient needs or generate scripts. Interconnectivity between all stakeholders and a 360° view of everything that…
EVERSANA’s Integrated Operations, Data-Driven Solutions and Digital Expertise Solve Key Challenges in Market Access and Field Deployment
Pharmaceutical manufacturers relying on the standard model for executing market access and field deployment strategies utilize resources inefficiently and redundantly. By integrating actions across operations, manufacturers can right size company resources, ensure affordability and increase speed…
Case Study: Defining the Rare Disease Patient Journey to Support Commercialization of Therapy
Rare diseases are complex, and with limited research available, therapeutic options are often limited. Gene therapy, a growing area of clinical research, is showing great promise in treatment that may be life-altering for patients with many…
Demystifying Data and Analytics – How to Advance Clinical and Business Objectives
The need to develop a strong, comprehensive data-analytics strategy to support pharma and healthcare initiatives cannot be stated strongly enough. Data is unbiased; it can validate hypotheses or provide direction. But the primary goal is to…
Navigating the Complexities of Patient Care with Digital and Human Touchpoints
Three Key Objectives Guide Program Development: Access, Affordability and Adherence Patients taking branded therapies to manage long-term health conditions are faced with a dizzying array of challenges, all of which can hinder access to medication, create…
Pharmaceutical Distribution – Right-Sizing the Channel Strategy for Maximum Impact
In recent years, there has been increasing appetite among manufacturers — and growing capabilities among specialized channel-distribution service providers — to shorten the value chain. When drug manufacturers reflexively commit to a distribution model that is…
FDA Moves Cybersecurity Into the Product Life Cycle
Due to rising cyber-attacks and the potential to cause harm to patients, medical facilities and hospitals, the U.S. Food and Drug Administration (FDA) has recently increased scrutiny of cyber controls in FDA premarket submissions of medical…
Impact of Patient Reported Outcome Measures on HTA Decisions for Rare Diseases
As rare diseases become an increasing area of global focus, pharmaceutical manufacturers are taking a closer look at how patient-reported outcomes (PROs) may be used to improve uptake in HTA evaluations. Although “rare” suggests not many…
EVERSANA Featured in NIH Study Detailing the Cost of Treating Rare Disease
“The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems” EVERSANA™ was the only data and analytic organization invited by a consortium of provider organizations and the NIH to…
Reigniting Revenue for Established Brands
Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease…